Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for Vitiligo
NCT02281058Phase 1Unknown
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2015
- Primary completion
- Nov 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in Vitiligo, sponsored by Brigham and Women's Hospital. Primary endpoint: Vitiligo Area and Severity Index at 24 weeks. Status: unknown.
02
Drugs
abatacept
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT02281058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281058.